ArticleJournal of neuro-oncology2018
Prognostic value of Ki-67 index in adult medulloblastoma after accounting for molecular subgroup: a retrospective clinical and molecular analysis.
Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 39 citations in OpenAlex.
- Quantification of Ki-67 labeling index in pediatric brain tumor immunohistochemistry images.Journal of neuropathology and experimental neurology · 2026Article
- An interpretable machine learning model for predicting prognosis of medulloblastoma integrating genetic and clinical features.Communications medicine · 2026Article
- Fusion of habitat analysis and deep learning on contrast-enhanced T1-weighted imaging for predicting Ki-67 status in pediatric brain tumors.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025Article
- Immunohistochemical detection of 5-hydroxymethylcytosine as a prognostic biomarker in non-WNT/Non-SHH medulloblastomas.Scientific reports · 2025Article
- Clinical and Molecular Characteristics and Outcome of Adult Medulloblastoma at a Tertiary Cancer Center.Cancers · 2024Article
- Prognostic value of Ki-67 index in primary intracranial tumors of infants.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023Article
- Exploring the relationship between age and prognosis in glioma: rethinking current age stratification.BMC neurology · 2022Article
- Radiomic signatures based on multiparametric MR images for predicting Ki-67 index expression in medulloblastoma.Annals of translational medicine · 2021Article
- Novel Molecular Hallmarks of Group 3 Medulloblastoma by Single-Cell Transcriptomics.Frontiers in oncology · 2021Article
- Loss of 5-Hydroxymethylcytosine as an Epigenetic Signature That Correlates With Poor Outcomes in Patients With Medulloblastoma.Frontiers in oncology · 2021Article
- Establishment of age group classification for risk stratification in glioma patients.BMC neurology · 2020Article
- Characterization of global 5-hydroxymethylcytosine in pediatric posterior fossa ependymoma.Clinical epigenetics · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
introductionMedulloblastoma (MB) is a rare primary brain tumor in adults. We previously evaluated that combining both clinical and molecular classification could improve current risk stratification for adult MB. In this study, we aimed to identify the prognostic value of Ki-67 index in adult MB.
methodKi-67 index of 51 primary adult MBs was reassessed using a computer-based image analysis (Image-Pro Plus). All patients were followed up ranging from 12 months up to 15 years. Gene expression profiling and immunochemistry were used to establish the molecular subgroups in adult MB. Combined risk stratification models were designed based on clinical characteristics, molecular classification and Ki-67 index, and identified by multivariable Cox proportional hazards analysis.
resultsIn our cohort, the mean Ki-67 value was 30.0 ± 11.3% (range 6.56-63.55%). The average Ki-67 value was significantly higher in LC/AMB than in CMB and DNMB (P = .001). Among three molecular subgroups, Group 4-tumors had the highest average Ki-67 value compared with WNT- and SHH-tumors (P = .004). Patients with Ki-67 index large than 30% displayed poorer overall survival (OS) and progression free survival (PFS) than those with Ki-67 less than 30% (OS: P = .001; PFS: P = .006). Ki-67 index (i.e. > 30%, < 30%) was identified as an independent significant prognostic factor (OS: P = .017; PFS: P = .024) by using multivariate Cox proportional hazards model.
conclusionsIn conclusion, Ki-67 index can be considered as a valuable independent prognostic biomarker for adult patients with MB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.